ReviewMolecular biology reports2026
The role of the adipose-derived Stromal Vascular Fraction (SVF) secretome as an immunomodulator in the treatment of chronic inflammatory diseases through NF-κB and macrophage reprogramming.
Review in Molecular biology reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Inflammatory responses trigger tissue damage through sustained activation of M1 macrophages and the NF-κB pathway. This review investigates the mechanism of action of the secretome derived from freshly isolated heterogeneous Stromal Vascular Fraction (SVF), distinct from culture-expanded stem cell conditioned media, in modulating the inflammatory response. This review summarizes the current literature on biochemical mechanisms that inhibit the NF-κB pathway and modulate the M1/M2 macrophage balance. SVF secretome components are proposed to modulate IKK complex phosphorylation and support the stabilization of IκBα, potentially hindering the nuclear translocation of p65/p50. At the same time, these components may encourage a metabolic shift to oxidative phosphorylation that supports M2-like polarization via the STAT6/PPAR-γ pathway. The SVF secretome is a potent immunomodulator that shifts microenvironments from destructive to regenerative. Recommendations: Further investigation should establish standardised GMP isolation methods and evaluate biochemical variability based on donor characteristics.
Indexed as
Identifiers
42771093What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.